AU6282896A - Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins - Google Patents

Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins

Info

Publication number
AU6282896A
AU6282896A AU62828/96A AU6282896A AU6282896A AU 6282896 A AU6282896 A AU 6282896A AU 62828/96 A AU62828/96 A AU 62828/96A AU 6282896 A AU6282896 A AU 6282896A AU 6282896 A AU6282896 A AU 6282896A
Authority
AU
Australia
Prior art keywords
immuno
gene therapy
solid tumors
effector proteins
interferons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62828/96A
Inventor
Idhaliz Flores
Sidney Pestka
Yacov Ron
Srijata Sarkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Medicine and Dentistry of New Jersey
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of AU6282896A publication Critical patent/AU6282896A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU62828/96A 1995-06-19 1996-06-18 Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins Abandoned AU6282896A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30295P 1995-06-19 1995-06-19
US000302 1995-06-19
PCT/US1996/010502 WO1997000085A1 (en) 1995-06-19 1996-06-18 Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins

Publications (1)

Publication Number Publication Date
AU6282896A true AU6282896A (en) 1997-01-15

Family

ID=21690885

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62828/96A Abandoned AU6282896A (en) 1995-06-19 1996-06-18 Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins

Country Status (3)

Country Link
EP (1) EP0835130A1 (en)
AU (1) AU6282896A (en)
WO (1) WO1997000085A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834323A1 (en) * 1996-09-30 1998-04-08 Introgene B.V. Cytokine gene therapy for treatment of malignacies
FR2760023B1 (en) 1997-02-21 2004-05-07 Commissariat Energie Atomique EUKARYOTIC CELLS EXPRESSING AT THEIR SURFACE AT LEAST ONE ISOFORM OF HLA-G AND THEIR APPLICATIONS
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
EP1987845B1 (en) 1997-11-20 2012-03-21 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
US7348015B2 (en) * 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
US7795020B2 (en) 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
CA2323604A1 (en) * 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
AU785241B2 (en) * 2000-05-17 2006-11-23 Cancure Limited Immune potentiating compositions
DK1346036T3 (en) 2000-11-29 2010-07-19 Univ Rochester Virus-free virus amplicon auxiliary particles and their applications
US8092791B2 (en) 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7674456B2 (en) 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
AU677165B2 (en) * 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens
NZ262630A (en) * 1993-02-17 1997-06-24 Sloan Kettering Inst Cancer Allogenic vaccine, modified retroviral vector coding for immunomolecules
CZ241795A3 (en) * 1993-03-19 1996-04-17 Boehringer Ingelheim Int Process for preparing a vaccine against malignant tumors and a complex for transfection

Also Published As

Publication number Publication date
EP0835130A1 (en) 1998-04-15
WO1997000085A1 (en) 1997-01-03

Similar Documents

Publication Publication Date Title
AU4787697A (en) Therapeutic gene
AU6255096A (en) Pegylated modified proteins
AU4008495A (en) Tcl-1 gene and protein and related methods and compositions
AU7398194A (en) Oligonucleotide modulation of protein kinase c
AU3972893A (en) Gene therapy using the intestine
AU1102399A (en) Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
AU4230196A (en) Treatment of pancreatic tumors with peptide yy and analogs thereof
AU4528493A (en) In vivo gene therapy with intron-free sequence of interest
AU7678196A (en) Methods and compositions for the delivery of monomeric proteins
AU8571598A (en) Cancer associated nucleic acids and polypeptides
AU3737297A (en) Bacteriophage-mediated gene therapy
AUPN741696A0 (en) Delivery of nucleic acids ii
AU6282896A (en) Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
AU2861695A (en) Mn gene and protein
AU8147194A (en) Recombinant adenoviruses for gene therapy in cancers
AU7705098A (en) Human tumor necrosis factor receptor-like protein 8
AU9222698A (en) Novel molecules of the tnfr-ligand-related protein family and uses thereof
AU3002497A (en) Treatment of human cancers with an adenovirus vector containing an interferon consensus gene
AU3092995A (en) Breast specific genes and proteins
AU4013495A (en) Chemokine-like proteins and methods of use
AU5020196A (en) Human fas gene promoter region
AU3003095A (en) Proteins associated with tumor necrosis factor receptor
AU1991799A (en) Molecules associated with the human suppressor of fused gene
AU3288497A (en) Mammalian tolloid-like gene and protein
AU1541699A (en) Human tumor necrosis factor-r2-like proteins